Global Lung Cancer Liquid Biopsy Market Size Likely to Grow at a CAGR of 10.2% By 2033

As per the current market research conducted by the CMI Team, the global Lung Cancer Liquid Biopsy Market size is expected to record a CAGR of 10.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 504.8 Million. By 2033, the valuation is anticipated to reach USD 1,210 Million.

Lung Cancer Liquid Biopsy Market: Growth Factors and Dynamics

• Increasing Incidence of Lung Cancer: Lung cancer remains one of the leading causes of cancer-related deaths globally. The rising incidence of lung cancer, especially non-small cell lung cancer (NSCLC), is a primary driver for the growth of the liquid biopsy market. Liquid biopsy offers a less invasive method for the detection and monitoring of lung cancer compared to traditional tissue biopsies.

• Advancements in Liquid Biopsy Technologies: Technological advancements in liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, circulating tumor cells (CTCs), and exosome analysis, have significantly improved the sensitivity and accuracy of detecting lung cancer biomarkers. These advancements have expanded the clinical utility of liquid biopsies in early detection, treatment selection, and monitoring of disease progression.

• Shift Towards Personalized Medicine: The paradigm shift towards personalized medicine and targeted therapies has fueled the demand for companion diagnostic tests, including liquid biopsy assays. Liquid biopsies enable the molecular profiling of tumors, facilitating the identification of specific genetic mutations (e.g., EGFR, ALK, ROS1) that can guide treatment decisions and improve patient outcomes.

• Rising Adoption of Liquid Biopsy in Clinical Practice: Liquid biopsy has gained acceptance in clinical practice due to its non-invasive nature, ability to provide real-time monitoring of tumor dynamics, and potential to overcome the limitations of tissue biopsies, such as tissue heterogeneity and sampling bias. Healthcare providers increasingly integrate liquid biopsy-based testing into routine clinical workflows for patients with lung cancer.

• Expanding Research and Development Activities: Pharmaceutical companies, diagnostic firms, and academic institutions are actively investing in research and development initiatives to enhance the capabilities of liquid biopsy technologies for lung cancer diagnosis and management. Collaborative efforts aim to validate novel biomarkers, improve assay sensitivity, and develop standardized protocols for liquid biopsy testing.

• Regulatory Support and Reimbursement Policies: Regulatory agencies, such as the FDA and EMA, have shown a willingness to expedite the approval and regulatory clearance of liquid biopsy-based tests for lung cancer diagnosis and monitoring. Additionally, the establishment of reimbursement policies by healthcare payers has encouraged the adoption of liquid biopsy assays by healthcare providers, ensuring financial sustainability and accessibility for patients.

Lung Cancer Liquid Biopsy Market: Partnership and Acquisitions

• In 2022, Illumina, Inc. partnered with Bristol Myers Squibb to advance companion diagnostics for precise oncology. Their collaboration focuses on enhancing therapy selection through innovations like the TSO 500 ctDNA liquid biopsy assay, offering comprehensive genomic profiling to guide personalized treatment decisions.

• In 2022, The US FDA approved 177Lu-PSMA-617, a novel treatment for metastatic prostate cancer. This targeted therapy, utilizing lutetium-177, signifies a significant advancement in addressing the needs of patients with metastatic prostate cancer, offering new hope in their treatment journey.

Report Scope

Lung Cancer Liquid Biopsy Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Lung Cancer Liquid Biopsy Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Healthcare Services: The COVID-19 pandemic led to significant disruptions in healthcare services globally, including routine cancer screenings and elective procedures. Many patients postponed or cancelled their appointments for lung cancer screening and monitoring, resulting in reduced demand for liquid biopsy testing.

• Supply Chain Disruptions: The pandemic disrupted supply chains for diagnostic reagents, laboratory equipment, and consumables, affecting the production and availability of liquid biopsy kits and assays. Delays in procurement and distribution of essential components hampered the capacity of laboratories to perform liquid biopsy testing efficiently.

• Resumption of Screening and Diagnostic Services: With the gradual easing of pandemic-related restrictions and the rollout of vaccination programs, healthcare facilities have resumed routine screening and diagnostic services for lung cancer. Increased awareness campaigns and outreach efforts aim to encourage patients to prioritize their lung cancer screenings, including the adoption of liquid biopsy as a non-invasive testing option.

• Emphasis on Telemedicine and Remote Monitoring: Healthcare providers have embraced telemedicine and remote monitoring solutions to ensure continuity of care for patients with lung cancer, including the integration of liquid biopsy-based testing into virtual consultations. Remote sample collection kits and decentralized testing platforms enable patients to undergo liquid biopsy testing conveniently, reducing the need for in-person visits to healthcare facilities.

• Investment in Research and Development: Despite the challenges posed by the pandemic, investment in research and development initiatives for liquid biopsy technologies has continued, focusing on improving assay performance, expanding biomarker panels, and validating novel targets for lung cancer detection and monitoring. Collaborative efforts between academia, industry, and regulatory agencies aim to accelerate the development and commercialization of next-generation liquid biopsy assays.

• Adoption of Hybrid Models and Digital Solutions: Laboratories and diagnostic companies are adopting hybrid testing models that combine traditional tissue biopsies with liquid biopsy testing to optimize patient care pathways for lung cancer diagnosis and management. Integration of digital pathology platforms, artificial intelligence algorithms, and cloud-based data analytics enhances the efficiency and accuracy of liquid biopsy data interpretation, enabling personalized treatment strategies for patients with lung cancer.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Lung Cancer Liquid Biopsy Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Lung Cancer Liquid Biopsy Market:

• Guardant Health Inc.
• Hoffmann-La Roche Ltd
• Biocept Inc.
• QIAGEN N.V.
• Natera Inc.
• Sysmex Corporation
• Trovagene Inc.
• Bio-Rad Laboratories Inc.
• Genomic Health Inc.
• Pathway Genomics Corporation
• Resolution Bioscience Inc.
• Inivata Ltd.
• OncoCyte Corporation
• Biodesix Inc.
• Menarini Silicon Biosystems S.p.A.
• Others

The Lung Cancer Liquid Biopsy Market is segmented as follows:

By Biomarker Type

• CTC (Circulating Tumor Cells)
• ctDNA (Circulating tumor DNA)
• Exosomes and RNA

By Application

• Small Cell Lung Cancer
• Non-Small Cell Lung Cancer

By End-User

• Diagnostic and Imaging Centres
• Hospitals
• Academic and Research Centers
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America